Comparative Pharmacology
Head-to-head clinical analysis: CALCIJEX versus RAYALDEE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIJEX versus RAYALDEE.
CALCIJEX vs RAYALDEE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcitriol, the active form of vitamin D, binds to the vitamin D receptor (VDR) in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone resorption. It also suppresses parathyroid hormone (PTH) synthesis and secretion via negative feedback.
Rayaldee (calcifediol) is a vitamin D3 analog that is converted to the active hormone calcitriol by 1-alpha-hydroxylase in the kidney. It acts as a vitamin D receptor agonist, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and suppressing parathyroid hormone (PTH) secretion. In CKD patients, it lowers elevated PTH levels.
Intravenous: 0.5 mcg three times per week during dialysis; may be increased by 0.25-0.5 mcg at 2-4 week intervals. Oral: 0.25 mcg daily; may be increased to 0.5 mcg daily.
30 mcg orally once daily at bedtime.
None Documented
None Documented
Terminal elimination half-life ranges from 5 to 10 hours in patients with normal renal function. In renal impairment, half-life may be prolonged up to 20 hours or more.
Terminal elimination half-life is approximately 14-19 hours, reflecting the extended-release formulation designed for once-daily dosing.
Primarily hepatic (biliary-fecal) elimination; approximately 2-4% excreted unchanged in urine. Small amount undergoes enterohepatic recirculation.
Primarily fecal via biliary excretion (70-80%); renal excretion accounts for <10% of total clearance.
Category C
Category C
Vitamin D Analog
Vitamin D Analog